Melissa Manno
Human Resources Officer chez KINIKSA PHARMACEUTICALS, LTD.
Profil
Melissa Manno is currently the Chief Human Resources Officer & Senior VP at Kiniksa Pharmaceuticals Ltd.
She previously worked as the Director-Human Resources at Synageva BioPharma Corp.
from 2014 to 2015 and as the Partner-Global Human Resources Business at Alexion Pharmaceuticals, Inc. from 2015 to 2017.
Ms. Manno completed her undergraduate degree at Keene State College.
Postes actifs de Melissa Manno
| Sociétés | Poste | Début |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Human Resources Officer | 01/06/2018 |
Anciens postes connus de Melissa Manno
| Sociétés | Poste | Fin |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/05/2017 |
| SYNAGEVA BIOPHARMA CORP | Human Resources Officer | 01/06/2015 |
Formation de Melissa Manno
| Keene State College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
